To amend the Federal Food, Drug, and Cosmetic Act to provide for expedited approval of priority nonprescription drugs, and for other purposes.
- Sponsor
- Rep. Latta, Robert E. [R-OH-5]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Jul 20, 2026
Bottom line
This bill aims to accelerate the availability of innovative and beneficial over-the-counter drugs to the public by streamlining the FDA's review process for designated priority nonprescription drugs.
What it actually does
This bill amends the Federal Food, Drug, and Cosmetic Act to establish a new designation for "priority nonprescription drugs." It allows the Secretary of Health and Human Services, through the FDA, to expedite the development and review of certain over-the-counter (OTC) drugs that meet specific criteria, such as addressing a novel nonprescription indication with a meaningful public health benefit or being a new molecular entity. The authority for this program is set to expire on September 30, 2032.
Proponents argue
Supporters argue that this bill will enhance public health by making innovative and beneficial nonprescription drugs available more quickly. By expediting the review process for drugs that address novel indications or introduce new active ingredients, it could provide consumers with more accessible and affordable treatment options, potentially reducing healthcare costs and improving self-care capabilities. They emphasize that it maintains existing evidentiary standards for safety and efficacy.
Opponents contend
Critics might express concerns that expediting drug approvals, even for nonprescription drugs, could inadvertently compromise safety standards or lead to less thorough review, potentially exposing the public to unforeseen risks. They might argue that the existing FDA review process, while sometimes slow, is crucial for ensuring drug safety and efficacy, and that creating a "priority" pathway could create a two-tiered system where some drugs receive less scrutiny.
The bill is concise and relatively easy to read, allowing a diligent reader to understand its core provisions within a short timeframe.
Section 1(a), inserting new Section 506M(a) into the FFDCA.
Creation of Priority Nonprescription Drug Designation
This provision authorizes the Secretary of Health and Human Services (acting through the FDA) to designate a nonprescription drug as a "priority nonprescription drug" if requested by the drug's sponsor and if it meets specific criteria. A "nonprescription drug" is defined as one not subject to prescription requirements under section 503(b)(1) of the FFDCA.
Supporters argue
Supporters argue this creates a clear incentive for pharmaceutical companies to invest in developing innovative over-the-counter options, knowing there's a mechanism to accelerate their review once safety and efficacy are established.
Critics contend
No specific opposition is typically raised against the creation of a designation pathway itself, though concerns might arise about the criteria or the implications of "priority" review.
Tradeoffs
Balances the desire for faster market access for beneficial drugs with the need for rigorous regulatory oversight.
Section 1(a), new Section 506M(d)
Eligibility Criteria and Exclusions
A drug is eligible for priority designation if it's intended for a novel nonprescription indication with a meaningful public health benefit, is a new molecular entity, or contains an active ingredient never before available OTC. However, drugs subject to a REMS (Risk Evaluation and Mitigation Strategy) or controlled substances are explicitly excluded from this designation.
Section 1(a), new Section 506M(e)
Expedited Review Mechanisms
If a drug receives priority designation, the FDA is directed to take actions to facilitate its development and expedite review. These actions may include holding frequent meetings with the sponsor, providing timely advice and interactive communication, involving senior management and experienced staff, assigning a cross-disciplinary project lead, and ensuring efficient trial design, including reliance on real-world evidence where appropriate.
Section 1(d)
Program Sunset
The authority provided to the Secretary of Health and Human Services under the new section 506M of the Federal Food, Drug, and Cosmetic Act shall cease to be effective on September 30, 2032. This means the program has a defined lifespan.
States that the amendment made by subsection (a) shall not be construed to alter the evidentiary standards or the information required for approval of a nonprescription drug under section 505 of the Federal Food, Drug, and Cosmetic Act.
Section 1(b)
Why it matters:Standard legislative practice to clarify intent and prevent misinterpretation, often placed outside the main amending text to ensure the new authority doesn't implicitly change existing fundamental requirements.
Case for: Supporters would argue this clause is essential to reassure the public and regulatory bodies that "expedited" does not mean "less rigorous" in terms of safety and efficacy evidence, maintaining the integrity of the approval process.
Case against: No direct case against, but critics might argue that even with this clause, the *process* of expedited review could inherently lead to less scrutiny, regardless of stated evidentiary standards, if resources are stretched.
Estimated impact: Ensures that the fundamental scientific bar for drug approval remains unchanged, impacting the perceived integrity of the FDA process and public trust in new OTC drugs.
Requires the Secretary of Health and Human Services to submit a report to Congress within 4 years of enactment, detailing the number of requests, approvals, and actual drug approvals under the new priority designation, resources used, and recommendations for improvement.
Section 1(c)
Why it matters:Standard legislative practice for oversight and future policy adjustments, often placed outside the main amending text to provide a mechanism for evaluating the program's effectiveness.
Case for: Proponents argue this ensures accountability and provides valuable data for Congress to assess the program's effectiveness and decide on its future, especially given the sunset clause, ensuring evidence-based policy decisions.
Case against: No direct case against, but some might view it as an additional bureaucratic burden on the FDA, requiring resources for data collection and reporting that could otherwise be used for drug review.
Estimated impact: Provides critical data for evaluating the success and efficiency of the priority nonprescription drug program, informing future legislative decisions on whether to extend or modify the authority.